Rise Advisors, LLC Black Diamond Therapeutics, Inc. Transaction History
Rise Advisors, LLC
- $242 Million
- Q2 2025
A detailed history of Rise Advisors, LLC transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Rise Advisors, LLC holds 646 shares of BDTX stock, worth $1,615. This represents 0.0% of its overall portfolio holdings.
Number of Shares
646Holding current value
$1,615% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BDTX
# of Institutions
95Shares Held
41.1MCall Options Held
45.1KPut Options Held
37K-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.4MShares$26 Million0.01% of portfolio
-
Vestal Point Capital, LP New York, NY5.6MShares$14 Million0.62% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$11.1 Million0.65% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$8.04 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V82.73MShares$6.83 Million0.1% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $90.8M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...